Intellia Therapeutics, Inc.
做多
已更新

NTLA - Inverse head & shoulders

175
An inverse head & shoulders pattern formed in the charts of Intellia, a company developing CRISPR gene-editing therapy. While CRISPR has not been approved to begin human trials in the US, it has already been tested on over 80 patients in China.

Target: $31 (previous closing high), or long term hold
Stop: $18 - $20
注释
Note: 2 other companies also developing CRISPR-Cas9 tech are CRSP and EDIT. Their stocks have skyrocketed the past month. It is advisable to wait for a correction before taking a position on them.
交易结束:到达目标
It wasn't a straightforward journey, but got there on time anyway! I hope everyone reading took profits at $31 (or even higher)

免责声明

这些信息和出版物并非旨在提供,也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。